Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, noviembre 03
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Vor Biopharma Inc
VOR
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$19.25
-0.43
-2.18%
Últ. Act.: Nov 2, 4:00 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Ganancias:
Los beneficios de Q3 2026 se publicaron el vie oct 30th, antes de la apertura del mercado
Vor Biopharma Financials
Vor Biopharma (VOR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
UPDATE: Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.70) by 14.29 percent. This is a 98.17 percent increase over losses of $(43.80) per share from
Benzinga Newsdesk
PRO
Vor Biopharma Q2 EPS $(1.16) Misses $(0.70) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.70) by 65.71 percent. This is a 99.54 percent increase over losses of $(251.24) per share from
Benzinga Newsdesk
PRO
Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 85.96 percent increase over losses of $(5.20) per share from the
Benzinga Newsdesk
PRO
Vor Biopharma Q4 Adj. EPS $(1.63) Beats $(1.64) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.63) per share which beat the analyst consensus estimate of $(1.64) by 0.61 percent. This is a 81.48 percent increase over losses of $(8.80) per share from the
Benzinga Newsdesk
PRO
UPDATE: Vor Biopharma Q3 Adj. EPS $(3.33) Misses $(3.25) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(3.33) per share which missed the analyst consensus estimate of $(3.25) by 2.37 percent. This is a 58.39 percent increase over losses of $(8.00) per share from the
Benzinga Newsdesk
PRO
Vor Biopharma Q3 EPS $(121.63) May Not Compare To $(3.32) Estimate
Benzinga Newsdesk
